Patent Classification

Treatment, Bacterial/Fungal Infection

1. Peptides for detection of antibody to Ehrlichia ewingii
    
2. Antibiotic formulation and method of treatment
    
3. Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells
    
4. Virus derived antimicrobial peptides
    
5. Two component Bacillus lantibiotic and methods for producing and using the same
    
6. Method for inhibiting the growth of antibiotic resistant of bacteria by using pentane-1,5-diol
    
7. Optimised formulation of tobramycin for aerosolization
    
8. Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
    
9. Protective anti-glucan antibodies with preference for .beta.-1,3- glucans
    
10. Lactobacillus living body activating Lactobacillus preparation and preventive or therapeutic agent for living body infection
     
11. Ehrlichia disulfide bond formation proteins and uses thereof
     
12. Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
     
13. Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
     
14. Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine
     
15. Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
     
16. Compositions and methods for treating intracellular diseases
     
17. Method for expression of small antiviral RNA molecules within a cell
     
18. Low concentration of peroxide for treating or preventing vaginal infections
     
19. Gene associated with leishmania parasite virulence
     
20. Peptides for detection of antibody to Anaplasma phagocytophilum
     
21. Use of milk serum apoproteins in the treatment of microbial or viral infection
     
22. Kahalalide compositions
     
23. Formulations and methods of administration of cephalotaxines, including homoharringtonine
     
24. Adhesin-specific nanoparticles and process for using same
     
25. Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides
     
26. Intranasal vaccine for use against disease caused by enterotoxigenic Escherichia coli
     
27. Detecting a bacterial process in chronic rhinosinusitis
     
28. Imunogenic complex comprising ribosomes
     
29. Method for determining the presence of bacteria resistant to cell lysing antibiotics
     
30. Chemical induced intracellular hyperthermia
     
31. Method and composition for reducing E. coli disease and enhancing performance
     
32. Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
     
33. Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
     
34. Vibrio cholerae with improved biological safety features in freeze dried form
     
35. Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
     
36. Use of cross-protection to identify novel vaccine candidates for infectious agents
     
37. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
     
38. Medicinal herbal composition for treating infection
     
39. Topical antifungal composition
     
40. Vaccines against Escherichia coli O157 infection
     
41. Staphylococcus antibodies
     
42. Method and composition for the treatment of adenoviral ocular infections
     
43. Immunotherapy for humans
     
44. Methods of inhibiting Helicobacter pylori
     
45. Therapy-enhancing glucan
     
46. Methods of inducing immune responses through the administration of auxtrophic attenuated dal/dat double mutant Listeria strains
     
47. Doxycycline metal complex in a solid dosage form
     
48. Antifungal remedy formulation for external application
     
49. Method for calibrating antibiotic disk diffusion testing of microorganisms
     
50. Method for screening agent acting on cell wall
     
51. Transformed cell with enhanced sensitivity to antifungal compound and use thereof
     
52. Attenuated gram negative bacteria
     
53. Antibodies for preventing and treating attaching and effacing Escherichia coli (AEEC) associated diseases
     
54. Moraxella catarrhalis BASB034 polypeptides and used thereof
     
55. Nonporous microparticle-prodrug conjugates for treatment of infection
     
56. Method for screening anti-bacterial agents
     
57. Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
     
58. Reducing tetracycline resistance in living cells
     
59. Antimicrobial theta defensins and methods of using same
     
60. Compositions and methods for immunotherapy of cancer and infectious diseases
     
61. Compositions and methods for treating infections using analogues of indolicidin
     
62. Outer membrane vesicles from gram negative bacteria and use as a vaccine
     
63. Monoclonal antibodies to the CLFA protein and method of use in treating infections
     
64. Oral pharmaceutical suspension of Cefdinir crystal
     
65. Compositions and methods comprising a protective antigen of Coccidiodes immitis
     
66. Compositions and methods for affecting virulence determinants in bacteria
     
67. Attenuated vaccine useful for immunizations against Coccidioides spp. infections
     
68. Compositions and methods for treatment of microbial infections
     
69. Escapin protein, a broadly antimicrobial compound from ink of the sea hare Aplysia californica, and uses thereof
     
70. Metabolic engineering of viomycin biosynthesis
     
71. Compositions comprising amphotericin B, methods, and systems
     
72. Compositions and methods for regulating bacterial pathogenesis
     
73. Use of ramoplanin to treat diseases associated with the use of antibiotics
     
74. Polypeptides containing polymorphisms of the repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica, their use in diagnostics, and in immunogenic compositions
     
75. Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions
     
76. Compositions and methods for enzymatic detachment of bacterial and fungal biofilms
     
77. Beta-defensins
     
78. Antibodies to novel proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections
     
79. Device and method for detecting antibiotic-inactivating enzymes
     
80. Polypeptide from haemophilus influenza
     
81. Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
     
82. Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
     
83. Method for treating bacterial infections in horses or pigs with tilmicosin
     
84. Tyrissamycin antibiotic
     
85. Methods and compositions for culturing spirochete and treating spirochetal diseases
     
86. Throat lozenge for the treatment of Streptococcus Group A
     
87. Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis
     
88. P. aeruginosa mucoid exopolysaccharide specific binding peptides
     
89. Antifungal pimaricin compositions and therapeutic methods employing same
     
90. Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan
     
91. Compositions and methods for treating or preventing pneumococcal infection
     
92. Method for treating onychomycosis
     
93. Pathogenic Escherichia coli associated protein
     
94. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
     
95. Host receptor for pathogenic bacteria
     
96. Non-invasive localization of a light-emitting conjugate in a mammal
     
97. Antifungal parenteral products
     
98. Use of RPL41 to treat infections and inhibit cancer
     
99. Multivalent macrolide antibiotics
     
100. Antigenic, non-toxic mutants of Clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith
      
101. Bandage composition containing phage associated lytic enzymes useful for treating dermatological infections
      
102. Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
      
103. Compositions and methods for reducing the transmissivity of illnesses
      
104. Methods of screening compounds useful for prevention of infection or pathogenicity
      
105. Antibodies to a fibrinogen binding protein of staphylococcus epidermidis
      
106. Amino acid sequences for therapeutic and prophylactic use against diseases due to clostridium difficile toxins
      
107. Methods of treating fungal infections using lupeol
      
108. Antibodies to the propeptide of Candida albicans and methods of use
      
109. Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
      
110. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
      
111. Drug targets in Candida albicans
      
112. Method of identifying putative antibiotic resistance genes
      
113. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
      
114. Immunogenic detoxified mutant E. coli LT-A-toxin
      
115. Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
      
116. Methods for screening and identifying host pathogen defense genes
      
117. Crystal forms of azithromycin
      
118. Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
      
119. Compositions and methods involving an essential Staphylococcus aureus gene and its encoded protein
      
120. Antimicrobial solution for both tropical and oral use
      
121. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
      
122. Kits for use in detecting resistance to streptogramin A and related compounds
      
123. Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
      
124. Antifungal compositions with improved bioavailability
      
125. Process for the preparation of pseudomonic acid a antibiotic by microbiological method
      
126. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
      
127. Recombinant soluble Fc receptors
      
128. Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
      
129. Pretreatment kit for saliva and pretreatment method for saliva
      
130. Topical treatment for prevention of ocular infections
      
131. Method for prevention and/or treatment of infections and inflammatory conditions using a combination of lactic acid bacteria
      
132. Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
      
133. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
      
134. Treatment of osteomyelitis with radiopharmaceuticals
      
135. Methods of reducing microbial resistance to drugs
      
136. Second release phase formulation
      
137. Anti-microbial biotherapeutic agents: alternatives to conventional pharmaceutical antibiotics
      
138. Antifungal parenteral products
      
139. Medicinal product package for eradication therapy
      
140. Alcohol-free anti-bacterial wipes
      
141. Topical spray for burn treatment and anti-infection
      
142. Composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from Glycyrrhiza glabra
      
143. Crystal forms of azithromycin
      
144. Pharmaceutical formulation comprising amoxycillin and clavulanate
      
145. Active immunization against clostridium difficile disease
      
146. Peptides for detection to Anaplasma phagocytophilum
      
147. Methods and compositions for inhibition of RNA splicing
      
148. Method of controlling release of antimicrobial agents in chewing gum
      
149. Methods of treating fungal infections using lupeol
      
150. Intravaginal drug delivery devices for the administration of an antimicrobial agent
      
151. Virulence genes, proteins, and their use
      
152. Macrolide solvates
      
153. Anti-fungal pharmaceutical compositions comprising an active ingredient prepared from Zingiber officinale
      
154. Process for preparing antibacterial and antioxidant fraction from Seabuckthorn (Hippophae rhamnoides L.)
      
155. Method for producing antibiotic composites
      
156. Anti-fungal composition
      
157. Detection of Candida
      
158. Vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
      
159. Methods to screen for antibiotic agents and their use in treatment of opportunistic infections
      
160. Penetrating antibiotic gel for soft tissue diseases
      
161. Antigenic protein originating in malassezia
      
162. Coccidial vaccine and methods of making and using same
      
163. Collagen-binding proteins from enterococcal bacteria
      
164. Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
      
165. Virus derived antimicrobial peptides
      
166. Treatment of E. faecium infection
      
167. Tampon for the treatment of Streptococcus Group B infections of the vagina
      
168. Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
      
169. Autoregulatory system for validating microbial genes as possible antimicrobial targets using a tetracycline-controllable element
      
170. Method for the treatment of bacterial eye infections
      
171. Stabilized difloxacin injectable solution
      
172. Dermatomycosis vaccine
      
173. Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
      
174. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil
      
175. Antibiotic sensitivity testing
      
176. Vaccines against Escherichia coli O157 infection
      
177. Composition containing porous microparticle impregnated with biologically-active compound for treatment of infection
      
178. Methods for the identification of inhibitors of asparagine synthase as antibiotics
      
179. Ophthalmic ointments for treating infective eye disease
      
180. Topical administration of basic antifungal compositions to treat fungal infections of the nails
      
181. Topical formulations of natamycin/pimaricin
      
182. Ionic silver complex
      
183. Virus derived antimicrobial peptides
      
184. Compositions isolated from bovine tissues and methods for their use
      
185. Microorganisms and assays for the identification of antibiotics
      
186. Anti-fungal powder having enhanced excipient properties
      
187. Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
      
188. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
      
189. Treatment of vulvovaginitis with spirostanol enriched extract from Tribulus terrestris
      
190. Methods for the identification of inhibitors of threonine synthase as antibiotics
      
191. Neisseria meningitidis antigen
      
192. Basb029 polynucleotide(s) and polypeptides from neisseria meningitidis
      
193. Compounds for treating fungal pathologies of the oral cavity
      
194. Collagen-binding proteins from streptococcus pyogenes
      
195. Adhesive treatment for oral fungal infection
      
196. Amoxicillin and potassium clavulanate dosage form
      
197. Attenuated microorganisms for the treatment of infection
      
198. Enterococcus antigens and vaccines
      
199. Vaccine against lipopolysaccharide core
      
200. Modified release pharmaceutical formulation comprising amoxycillin
      
201. Oxazolidinones to treat eye infections
      
202. Methods for the identification of inhibitors of histidinol-phosphate as antibiotics
      
203. Bandage composition containing a phage associated lytic enzyme
      
204. Methods for the identification of antimicrobial compounds
      
205. Genes identified as required for proliferation in Escherichia coli
      
206. Method of determining evolutionary potential of mutant resistance genes and use thereof to screen for drug efficacy
      
207. Diagnosis of histoplasmosis using antigens specific for H. capsulatum
      
208. Bacterial superantigen vaccines
      
209. Retrocyclins: antiviral and antimicrobial peptides
      
210. Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
      
211. Fatty acid antimicrobial
      
212. Mutacin I biosynthesis genes and proteins
      
213. Methods for the identification of inhibitors of 5-aminolevulinate synthase as antibiotics
      
214. Chewing gum containing phage associated lytic enzymes for treating streptococcal A infections
      
215. Passive immunization against clostridium difficile disease
      
216. Methods of reducing microbial resistance to drugs
      
217. Nasal solution containing a broad spectrum microbicide and a method for its use
      
218. Method for treating diseases of fungal, yeast, and prion protein etiology
      
219. Rnase P polypeptides, polynucleotides, and methods using their mechanisms of action
      
220. Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
      
221. Methods and compositions for prevention and treatment of Clostridium difficile-associated diseases
      
222. Methods for the identification of inhibitors of homocitrate synthase as antibiotics
      
223. Immunological activity for a peptide of the limulus anti-LPS factor
      
224. Penicillin binding protein from Streptococcus pneumoniae
      
225. Administration of oxazolidinones for transdermal delivery
      
226. Low-rigidity liposomal formulation
      
227. Amoxicillin-clarithromycin antibiotic composition
      
228. Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
229. C1 bacteriophage lytic system
      
230. Antibiotic/medicated gutta percha point
      
231. Compositions comprising nitrofurantoin and uva ursi
      
232. Composition for treatment of drug resistant bacterial infections and a method of treating drug resistant bacterial infections
      
233. Moraxella catarrhalis BASB034 polypeptides and uses thereof
      
234. Lymphocyte-derived antimicrobial protein (LDAP) and methods of isolating and producing and using the protein
      
235. Pediatric formulation of gatifloxacin
      
236. Human therapeutic uses of BPI protein products
      
237. Bioabsorbable drug delivery system for local treatment and prevention of infections
      
238. Method of screening anti-mycobacterial molecules
      
239. Method of treating or preventing microbial infections with loperamide
      
240. Method and compositions for the control or eradication of Helicobacter pylori
      
241. Use of metal complexes to treat gastrointestinal infections
      
242. Detection and treatment of infections with immunoconjugates
      
243. Treatment and diagnosis of infections of gram positive cocci
      
244. CaESS1: a Candida albicans gene, methods for making and using, and targeting it and its expression products for antifungal applications
      
245. Lanthionine antibiotic compositions and method
      
246. Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
      
247. Combinations of fungal cell wall degrading enzyme and fungal cell membrane affecting compound
      
248. EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
      
249. Method for inhibiting melanogenesis and uses thereof
      
250. Fungal efflux pump inhibitors
      
251. Recombinant Sef14 fimbrial protein from Salmonella
      
252. Stabilized cefuroxime axetil
      
253. Use of granulysin as an antimicrobial agent
      
254. Human xenografts for microbicide testing and anatomical modeling
      
255. Long-acting antimicrobials
      
256. Method for promoting the growth of gram-positive bacilli and increasing the acidity in vagina
      
257. Use of bacterial phage associated lysing enzymes for treating dermatological infections
      
258. Ringworm vaccine
      
259. Method for the broad based treatment of infections especially infections of organs such as the skin and vagina
      
260. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
      
261. Composition for treatment of a bacterial infection of the digestive tract
     
     
262. Subversion of bacterial resistance by low solubility antibiotics
     
     
263. Antibacterial composition for topical administration containing antibiotic
     
     
264. Topical suspension formulations containing ciprofloxacin and dexamethasone
     
     
265. Prokaryotic polynucleotides polypeptides and their uses
     
     
266. Method of selecting bacterial strains
     
     
267. Intraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same
     
     
268. Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections
     
     
269. Pseudomonas treatment composition and method 
     
     
270. Reptilian-derived peptides for the treatment of microbial infections
      
271. Immunomodulatory and antimicrobial materials, their preparation and use
      
     
272. Mammalian-derived peptides for the treatment of microbial infections
      
     
273. Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
      
     
274. Fungal antigens and process for producing the same
      
     
275. Methods of treating microbial infection and therapeutic formulations therefor
      
     
276. Anti-bacterial antibodies and methods of use
      
277. Method of sensitizing microbial cells to antimicrobial compound
      
278. Anti-fungal formulation active against a broad spectrum of dermatophytoses
      
     
279. Antibiotic cryptdin peptides and methods of their use
      
     
280. Staphylococcus aureus antigen-containing whole cell vaccine
      
     
281. Method of treating a bacterial infection comprising administering amoxycillin
      
     
282. Antimicrobial agents isolated from aloe vera
      
     
283. Methods and compositions for the treatment and prevention of Staphylococcal infections
      
284. Magnesium quinolone antibiotics
      
     
285. Therapeutic uses of bactericidal/permeability-increasing protein dimer products
      
     
286. Recombinant mycobacterial vaccine
      
     
287. Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase
      
     
288. Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae
      
     
289. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis

Treatment, Balance Impairments

1. Treatment of balance impairments

Treatment, Behavior Chemotherapy

1. Methods for treating pervasive development disorders
    
2. Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
    
3. Behavior chemotherapy
    
4. Behavior chemotherapy

Treatment, Bile Acid Sequestrants/Related Illnesses

1. Strains Of Bacteria And Pharmaceutical Composition Containing One Or More Of Such Strains And Use Of Same For Preventing And Treating Diseases Associated With Or Caused By Altered Metabolism Of Bile Acids
    
2. Polymers containing guanidinium groups as bile acid sequestrants

Treatment, Bioartificial Organ

1. Artificial dermis and production method therefor
    
2. Mx-1 conditionally immortalized cells

Treatment, Bipolar/Mania Related Disorders

1. Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
    
2. Method of determining susceptibility to bipolar disorders
    
3. Methods for the treatment of bipolar disorder using carbamazepine
    
4. Method of treating bipolar disorders using deuterium-substituted carbonate
    
5. Method for the treatment of mania and bipolar disorder
   
   
6. Omega-3 fatty acids in the treatment of bipolar disorder

Treatment, Birth, Preterm

1. Methods and materials for preterm birth prevention

Treatment, Bladder Related Disorders/Cancer

1. Patch for replacement of a portion of bladder wall following partial cystectomy
    
2. Method of treating bladder and lower urinary tract syndromes
    
3. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
    
4. Methods of selecting compounds for modulation of bladder function
    
5. Method for preparing solid dosage form of desmopressin
    
6. Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
    
7. Antibody to bladder cancer nuclear matrix protein and its use
    
8. Medical compositions for intravesical treatment of bladder cancer
    
9. Transdermal therapeutic system TTS containing tolterodine
    
10. Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
     
11. Agent for treatment of bladder troubles
     
12. Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
     
13. Use of garlic extract as both preventive and therapeutic agents for human prostate and bladder cancers
     
14. Composition and method for the treatment of bladder cancer
     
    
15. Gene therapy for regulating bladder smooth muscle tone
     
    
16. Remedies for bladder disorders

Treatment, Blood Related Disorders/Coagulation/Hemophilia

1. Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
    
2. Degraded TPO agonist antibody
    
3. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
    
4. Blood-viscosity reducing agent
    
5. Method for treating blood coagulation disorders
    
6. Medical emulsion of perfluororganic compounds and method for the production thereof
    
7. Embolization using degradable crosslinked hydrogels
    
8. Multi-part substitution infusion fluids and matching anticoagulants
    
9. Method for making a high oxygen affinity modified hemoglobin for oxygen transport
    
10. Multiplexed detection of anti-red cell alloantibodies
     
11. Methods for treating blood coagulation disorders
     
12. Glycine betaine and its use
     
13. Method of administering porcine B-domainless fVIII
     
14. Therapeutic preparation of very high purity FVIIa and method for obtaining same
     
15. Factor IXa for the treatment of bleeding disorders
     
16. Heparin prodrugs and drug delivery stents formed therefrom
     
17. Erythropoietin receptor binding antibodies
     
18. Methods of treating hemophilia or von willebrand disease with p-selectin
     
19. Method for diagnosis and treatment of haemophilia A patients with an inhibitor
     
20. Transfusion registry network providing real-time interaction between users and providers of genetically characterized blood products
     
21. Gene therapy agent for Haemophilia B and its preparation method
     
22. Method for determination of platelets quality
     
23. Blood substitutes
     
24. Modified vitamin K-dependent polypeptides
     
25. Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
     
26. Method for improving oxygen transport by stored red blood cells
     
27. High capacity recombinant adenoviral vector for treatment of hemophilia A
     
28. Oxygenated albumin for use as blood and blood extender
     
29. Oral treatment of hemophilia
     
30. Human-type anti-blood coagulation factor VIII antibody
     
31. Anticoagulant composition
     
32. Human coagulation factor VII variants
     
33. Clot-specific streptokinase proteins possessing altered plasminogen activation characteristics and a process for their preparation
     
34. Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
     
35. Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
     
36. Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L
     
37. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
     
38. Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
     
39. Human anti-factor IX/IXa antibodies
     
40. Pharmaceutical composition comprising factor VIII and neutral liposomes
     
41. Protease for activating clotting factor VII
     
42. Composition comprising multipotent neural stem cells for generation of hematopoietic cells
     
43. Fibrinogen bandages and arterial bleeding models and methods of making and using thereof
     
44. Saratin for inhibiting platelet adhesion to collagen
     
45. Glycine betaine and its use
     
46. Methods for oxygen transport comprising a high oxygen affinity modified hemoglobin
     
47. Inactivation resistant factor VIII
     
48. Method and compositions for inhibiting thrombin-induced coagulation
     
49. Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
     
50. Vitro methods for screening for blood coagulation disorders using metal ions
     
51. Antithrombin H-helix mutants
     
52. Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses
     
53. Protein for blocking platelet adhesion
     
54. Modified vitamin K-dependent polypeptides
     
55. Method of treating heparin-induced thrombocytopenia
     
56. Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography
     
57. Hemostatic sponge based on collagen
     
58. Methods and compositions for control of blood coagulation
     
59. Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
     
60. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
     
61. Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
     
62. Protease for activating clotting factor VII
     
63. High molecular weight derivatives of vitamin K-dependent polypeptides
     
64. Pharmaceutical composition comprising ticlopidine and Ginkgo biloba extract
    
    
65. Methods for using the obese gene and its gene product to stimulate hematopoietic development
    
    
66. Methods for the localized delivery of agents to blood vessels
     
    
67. Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation
     
    
68. Immunoglobulin-like domains with increased half-lives
     
    
69. Methods for treating hypercoagulable states or acquired protein C deficiency
     
    
70. Fibrinogen-coated microspheres
     
    
71. Amphiphilic polysaccharide derivatives
     
    
72. Method for treating hemophilia A and B and AIDS and devices used therein

Treatment, Bone/Tissue Repair/Growth/Mineralization

1. Methods useful in the treatment of bone resorption diseases
    
2. Polynucleotides encoding heavy and light chains of antibodies to OPGL
    
3. Methods for enhanced production of bone morphogenetic proteins
    
4. Self-setting absorbable composites and applications thereof
    
5. Intracellular delivery of osteoinductive proteins and peptides
    
6. Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
    
7. GDF-9/BMP-15 modulators for the treatment of bone disorders
    
8. Bone precursor cells: compositions and methods
    
9. Methods for promoting growth of bone, ligament, and cartilage
    
10. Platelet-derived growth factor compositions and methods of use thereof
     
11. Composition for an injectable bone mineral substitute material
     
12. Calcium phosphate delivery vehicles for osteoinductive proteins
     
13. Method and compositions for promoting osteogenesis
     
14. Method and system for modeling bone structure
     
15. Multidirectional morphology and mechanics of osteonic lamellae
     
16. Method and composition for treatment of skeletal dysplasias
     
17. Protein and process for producing the same
     
18. Method for promoting bone formation
     
19. Differentiation of adipose stromal cells into osteoblasts and uses thereof
     
20. Method of increasing bone toughness and stiffness and reducing fractures
     
21. Peptide with osteogenic activity
     
22. Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
     
23. Methods of altering calcium transport
     
24. Isoforms of the human vitamin D receptor
     
25. Use of calmodulin to promote bone regeneration
     
26. Method of increasing bone toughness and stiffness and reducing fractures
     
27. Bioceramic compositions
     
28. Method of preparing a poorly crystalline calcium phosphate and methods of its use
     
29. Method of enhancing bone density
     
30. Resorbable polymer composition, implant and method of making implant
     
31. Pharmaceutical composition useful for inhibition of osteoclast formation and a process for the extraction of mussel hudrolysate from indian green mussel
     
32. Vitamin formulation for enhancing bone strength
     
33. Polymethylmethacrylate augmented with carbon nanotubes
     
34. Three-dimensional hydrogel/cell system
     
35. Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
     
36. Purification and use of human recombinant cartilage oligomeric matrix protein
     
37. Modified proteins of the TGF-.beta. superfamily, including morphogenic proteins
     
38. Continuous acidification demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby
     
39. Antibiotic calcium phosphate coating
     
40. Antibodies associated with alterations in bone density
     
41. Calcium dietary supplement
     
42. Mineralization and biological modification of biomaterial surfaces
     
43. SOX-9 gene and protein and use in the regeneration of bone or cartilage
     
44. Method for diagnosing bone dysbolism
     
45. Implantable putty material
     
46. Use of a dipeptide for stimulating repair processes
     
47. Implant comprising calcium cement and hydrophobic liquid
     
48. Plant extracts for the treatment of increased bone resorption
     
49. Method for improving bone mineralization
     
50. Peptide and osteogenetic accelerator
     
51. Treatment of subnormal bone mineral density
     
52. Method for induction of differentiation of osteoclasts
     
53. Osteoclast secreted chemokine and uses thereof
     
54. Screening methods for identifying modulators of proliferation and differentiation of bone cells
     
55. Bone mineralization proteins, DNA, vectors, expression systems
     
56. FGFR3 as a marker for mesenchymal skeletal progenitor cells
     
57. Methods of reducing bone loss with CD40 ligand
     
58. Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
     
59. Method for inducing osteoblast differentiation of human extramedullary adipose tissue cells
     
60. Matrix-free osteogenic devices, implants and methods of use thereof
     
61. Hollow bone mineral-like calcium phosphate particles
     
62. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
    
    
63. Genetic engineering of cells to enhance healing and tissue regeneration
    
    
64. Uses of bone morphogenetic proteins
    
    
65. Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
    
    
66. Osteocyte cell lines
    
    
67. Bone morphogenetic proteins and their use in bone growth
    
    
68. Bioactive, degradable composite for tissue engineering
     
    
69. Osteogenic devices
     
    
70. Peptides which promote bone-forming cell attraction and adhesion
     
    
71. Injectable hyaluronate-sulfated polysaccharide conjugates
     
    
72. Injectable bio-active glass in a dextran suspension

Treatment, Bone Cancer/Tumor/Related Disorders

1. High dose radionuclide complexes for bone marrow treatment
    
2. Skeletal-targeted radiation to treat bone-associated pathologies
    
3. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
    
4. Treatment of bone-associated cancers
    
5. Nucleic acids encoding chimeric proteins comprising BMP-2 and a proteinase inhibitor
    
6. Treatment of osteomyelitis with radiopharmaceuticals
    
7. Interferon-beta use in the treatment of ewing's family of tumors
    
8. Treatment of bone cancer
    
9. Methods for treating bone tumors

Treatment, Bone Marrow Transplant

1. Treatment of malignant tumor
    
2. Methods of screening for compounds that improve engraftment
    
3. Gene therapy by cell specific targeting
    
4. Relationship of ABC transport proteins with hematopoietic stem cells and methods of use thereof
    
5. Composition comprising multipotent neural stem cells for generation of hematopoietic cells
    
6. Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
    
7. Vectors encoding a modified low affinity nerve growth factor receptor

Treatment, Botulism

1. Post-translational modifications and clostridial neurotoxins
    
2. Antibodies against type A botulinum neurotoxin
    
3. Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    
4. Recombinant vaccine against botulinum neurotoxin
    
5. Type F botulinum toxin and use thereof
    
6. Antibodies against type a botulinum neurotoxin
    
7. Botulinum neurotoxin vaccine

Treatment, Brain/CNS Tumor/Glioblastomas

1. Immunotherapy against several tumors including neuronal and brain tumors
    
2. Cancer vaccines and vaccination methods
    
3. Therapeutic method of treating brain trauma in rodents with VCP
    
4. Method of preventing and treating brain infarction
    
5. NFIA in glial fate determination, glioma therapy and astrocytoma treatment
    
6. Methods of obtaining neural stem cells
    
7. Binding molecules for the treatment of myeloid cell malignancies
    
8. Neural stem cells and use thereof for brain tumor therapy
    
9. Reshaped human antibody to human medulloblastoma cells
    
10. Chimeric immunoreceptor useful in treating human gliomas
     
11. Use of taurolidine to treat tumors
     
12. Neural stem cells and use thereof for brain tumor therapy
     
13. Pharmaceutical composition for boron neutron capture therapy containing triphenylboroxin
     
14. Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
     
15. Alginate capsules for use in the treatment of brain tumor
     
16. Diagnosis and treatment of malignant neoplasms
     
17. Diagnosis and treatment of malignant neoplasms
     
18. Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
     
19. Diagnosis and treatment of malignant neoplasms
     
20. Treatment of cancer with thymidine in combination with temozolamide
     
21. Method for inhibiting brain tumor or colon carcinoma
     
22. Adenovirus-mediated gene therapy
     
23. Method for gene transfer to the central nervous system
     
24. Methods for inhibiting brain tumor growth
     
25. Edelfosin for the treatment of brain tumors
     
26. Replication-competent herpes simplex virus
     
27. Method of diagnosing and treating gliomas

Treatment, Breast/Mammary Cancer/Diseases

1. Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
    
2. Targeting PAX2 for the treatment of breast cancer
    
3. Breast cancer eradication program
    
4. Treatment of metastatic breast cancer
    
5. Breast, gastric and prostate cancer associated antigens and uses therefor
    
6. Compositions and methods for the therapy and diagnosis of breast cancer
    
7. Deuterium-enriched capecitabine
    
8. Pharmaceutical preparations for treatments of diseases and disorders of the breast
    
9. Treatment of mastalgia with 4-hydroxy tamoxifen
    
10. Estrogen receptors and methods of use
     
11. Prediction of likelihood of cancer recurrence
     
12. IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
     
13. DNA vaccines against tumor growth and methods of use therof
     
14. Immunogenic peptides for the treatment of prostate and breast cancer
     
15. Herbal composition for treating cancer
     
16. Predicting outcome with tamoxifen in breast cancer
     
17. Reduction of breast density with 4-hydroxy tamoxifen
     
18. Method of administering and using VEGF inhibitors for the treatment of breast cancer
     
19. Breast cancer prognostic portfolio
     
20. Identification of viral agents in breast ducts and antiviral therapy therefore
     
21. Matriptase, a serine protease and its applications
     
22. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
     
23. Methods for treating breast cancer using a mammary cell growth inhibitor
     
24. Cancer treatment composition and method using natural plant essential oils
     
25. Methods and compositions for inhibition of metastasis
     
26. Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
     
27. Identification of viral agents in breast ducts and antiviral therapy therefore
     
28. Testis-specific tubulin tyrosine-ligase-like protein, BGS42
     
29. Glypican-1 in human breast cancer
     
30. G-protein coupled receptors
     
31. Gene expression profiling in biopsied tumor tissues
     
32. Antibodies to the K12 protein
     
33. Breast cancer specific gene 1
     
34. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
     
35. Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use
     
36. Drug screening using a proline-rich nuclear receptor co-regulatory protein/nuclear receptor co-expression system
     
37. Method of diagnosing and monitoring malignant breast carcinomas
     
38. Compositions and methods for the therapy and diagnosis of breast cancer
     
39. Compositions and methods for the therapy and diagnosis of breast cancer
     
40. Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
     
41. Method of diagnosing breast cancer using nipple fluid
     
42. Methods for reducing the risk of breast cancer in and improving the health of women
     
43. Method of identifying and treating invasive carcinomas
     
44. Compositions and methods for the treatment and diagnosis of breast cancer
     
45. Phytochemotherapy for cancer
     
46. Aberrantly methylated genes as markers of breast malignancy
     
47. Three-dimensional in vitro model of human preneoplastic breast disease
     
48. Cancer treatment composition and method using natural plant essential oils
     
49. Methods for detection and diagnosing of breast cancer
     
50. Method and antibody for imaging breast cancer
     
51. Detection and treatment of breast disease
     
52. Treatment of breast cancer
     
53. Methods for diagnosing and evaluating cancer
     
54. Mammaglobin, a secreted mammary-specific breast cancer protein
     
55. Human endogenous retrovirus in breast cancer
     
56. Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
     
57. Identifying, monitoring, and treating women for breast precancer or cancer
     
58. Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
     
59. Metastatic breast and colon cancer regulated genes
     
60. Identification of differentially methylated and mutated nucleic acids
     
61. Flocculated suspension of megestrol acetate
     
62. Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue
     
63. Compositions for the treatment and diagnosis of breast cancer and methods for their use
     
64. Compositions and methods for the treatment and diagnosis of breast cancer
     
65. Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
     
66. Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
     
67. Compositions for treatment and diagnosis of breast cancer and methods for their use
     
68. Methods for treating breast cancer using Mammastatin
     
69. Ligand antagonists for treatment of breast cancer
     
70. Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
    
    
71. Antisense modulation of BTAK expression
    
    
72. Method for detection and treatment of breast cancer
     
    
73. Detection and treatment of breast disease

Treatment, Bronchitis

1. Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic

Treatment, Brucellosis

1. Live vaccine against Brucellosis

Treatment, Burns

1. Beta-adrenergic blockade reversal of catabolism after severe burn
    
2. Composition for pain mediation and apparatus and method of use thereof
    
3. Topical spray for burn treatment and anti-infection
    
4. Use of oxandrolone in the treatment of burns and other wounds
    
5. Microclysmic gel for treatment of tissue trauma and burns
    
6. Topical spray for burn treatment and anti-infection
    
7. Composition for pain mediation and apparatus and method of use thereof